Saphetor aims to become the world’s reference in bioinformatics tools to process large-scale genomics. Genomics data analysis is often inconsistent and time consuming, with currently no standard in data interpretation. In particular, data analysis and interpretation is the bottleneck in early cancer detection. It is very hard to find comprehensive information on gene variants in the landscape of human genomics, which leads to imprecise diagnostics and inefficient therapies.

Saphetor provides algorithms and tools for aggregating, harmonizing and analyzing large amounts of genome data across multiple disparate sources.

Saphetor’s VarSome suite offers a consistent genome-scale analysis and annotation of NGS data (genome-scale analysis is the ability to give a complete description of the completely human genome, roughly 21’000 genes).

The product helps to improve outcomes for patients by offering clinicians data-driven solutions to make faster, more accurate diagnoses from the variant database and thus to customize therapies.


CEO: Andrea Massouras

Headquarters: Lausanne, Switzerland

Initial investment date: February 2016

Site: saphetor.com

Latest news

Saphetor and Roche join forces!

Saphetor has signed a new partnership with Roche Turkey giving the pharma giant access to its network to facilitate scientific collaborations on new treatments for Spinal Muscular Atrophy.

Read More »